Drug Profile
Research programme: eye disorders therapy - Alcon/Amgen
Latest Information Update: 15 Apr 2019
Price :
$50
*
At a glance
- Originator Amgen
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Eye disorders
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon
- 01 May 2006 Preclinical trials in Eye disorders in USA (unspecified route)